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Thioredoxin-interacting protein (TXNIP) is an a-arrestin
that can bind to and inhibit the antioxidant protein thio-
redoxin (TXN). TXNIP expression is induced by glucose
and promotes b-cell apoptosis in the pancreas, and
deletion of its gene in mouse models protects against
diabetes. TXNIP is currently studied as a potential new
target for antidiabetic drug therapy. In this study, we
describe a family with a mutation in the TXNIP gene
leading to nondetectable expression of TXNIP protein.
Symptoms of affected family members include lactic
acidosis and low serum methionine levels. Using
patient-derived TXNIP-deficient fibroblasts and myo-
blasts, we show that oxidative phosphorylation is
impaired in these cells when given glucose and pyru-
vate but normalized with malate. Isolated mitochondria
from these cells appear to have normal respiratory
function. The cells also display a transcriptional pattern
suggestive of a high basal activation of the Nrf2 tran-
scription factor. We conclude that a complete lack of
TXNIP in human is nonlethal and leads to specific met-
abolic distortions that are, at least in part, linked to
a deficient respiration on pyruvate. The results give
important insights into the impact of TXNIP in humans
and thus help to further advance the development of
antidiabetic drugs targeting this protein.
Thioredoxin (TXN)–interacting protein (TXNIP), also
known as TXN-binding protein 2 (TBP-2) or vitamin
D3–upregulated protein 1 (VDUP1), was originally iden-
tified as a vitamin D3 target gene in a cancer cell line (1). It
was later found to bind and inhibit TXN, thus controlling
TXN activity and cellular redox homeostasis (2,3). The
TXN system is a major cellular system for control of redox
state, antioxidant defense, and several signaling pathways
(3,4). The relevance of the TXN system is underscored by
the fact that its aberrations are related to onset and/or
progression of several pathologies (3,5). In this regard, due
to its direct interactions with TXN, the role of TXNIP in
control of cellular redox balance has been largely studied
(3,6). However, it also seems clear that TXNIP has several
additional functions not necessarily related to its inhibi-
tion of TXN, including activation of the NLRP3 inflam-
masome (3,7–9) and suppression of the activities of the
nuclear factor (erythroid-derived 2)–like 2 (Nrf2) tran-
scription factor (10). This is interesting, because Nrf2 also
suppresses TXNIP expression (11), which yields a complex
web of possible regulation pathways among TXNIP, TXN,
Nrf2, and the inflammasome since TXN and Nrf2 are
also intimately linked with each other as well as with
NLRP3 inflammasome activation (10,12,13). It is also
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noteworthy that Nrf2 activation has major metabolic
effects, it channels glucose to anabolic and reductive path-
ways, and its activation seems to protect from develop-
ment of diabetes (14,15). These observations collectively
suggest that although TXNIP activities may affect cellular
redox control by binding and inhibiting TXN, its activities
may also be related to signaling events that are not
necessarily linked to its direct inhibition of TXN and
should be considered in relation to Nrf2 activation.
TXNIP is an ;43-kDa protein that belongs to the
a-arrestin family of proteins. The a-arrestins are known
as multifunctional scaffolding proteins involved in pro-
tein–protein interactions that mediate a wide array of
signaling processes (16). Indeed, compelling evidence
has shown a role for TXNIP in metabolic control partially
independent of its ability to bind TXN. A series of genetic
analyses to pinpoint mutations involved in a spontaneous
mouse model of familial hyperlipidemia led to the identi-
fication of a nonsense mutation in the Txnip gene (17,18).
Subsequent studies using Txnip-null mouse genetic models
have revealed an important role of TXNIP in regulation of
metabolism. Txnip-knockout mice fail to coordinate the
transition between the fed and fasted states, as they fail to
maintain normoglycemia upon fasting, and they display
abnormally high ketosis and plasma levels of fatty acids
compared with their control counterparts (19,20). TXNIP
correspondingly appears to be an important regulator of
glucose homeostasis by fine-tuning gluconeogenesis in the
liver (20), and TXNIP contributes to regulation of cardiac
energy metabolism (21,22). Txnip deficiency in mice fed
a high-fat diet promotes enhanced adipogenesis while
preserving insulin sensitivity (23), and even in the strong
diabetic mouse model of leptin-deficient BTBRob/ob mice,
Txnip deficiency protects the pancreatic b-cells from apo-
ptosis and thus the mice from developing diabetes (24).
Importantly, insulin and cellular glucose influx recip-
rocally regulate TXNIP expression in humans, with glucose
influx upregulating TXNIP expression and insulin sup-
pressing it (25), which is consistent with a recent study
revealing that IGF-1 can suppress TXNIP expression (26).
Although it was shown that TXNIP expression was upre-
gulated in patients with type 2 diabetes mellitus, genetic
linkage association studies could not identify any varia-
tions in the TXNIP gene associated with type 2 diabetes
mellitus onset or progression (25). Other genome-wide
studies have, however, discovered associations between
TXNIP gene variants and diabetes (27–29). Thus, collec-
tively, several studies have shown that TXNIP promotes
diabetes, with hyperglycemia and pancreatic b-cell death,
and TXNIP has thereby been proposed as a promising drug
target for the treatment of diabetes (8,30). Loss-of-func-
tion of TXNIP in humans has, however, not yet been
described, and it has remained unknown whether TXNIP
is essential in humans or what pathologies its lack of
expression may yield.
In this study, we identified a family with three sib-
lings who bear a homozygous point mutation creating
a premature stop codon in the TXNIP gene, leading to
complete absence of detectable TXNIP protein. Our study
demonstrates that abolished TXNIP function is nonle-
thal in humans and leads to a relatively mild metabolic
phenotype linked to less efficient utilization of glucose.
These results may collectively further support the notion
that TXNIP can be a promising antidiabetic drug target in
humans.
RESEARCH DESIGN AND METHODS
Ethical Considerations
This study was approved by the regional ethics committee
in Stockholm, Sweden. Informed consent was obtained
from both parents of the patients.
Genetic Investigations
Whole-exome sequencing was performed on genomic
DNA from the subjects using the HiSeq 2500 platform
(Illumina) and the Agilent SureSelect Human All Exon V4
whole-exome kit (Agilent, Santa Clara, CA). The resulting
sequences were analyzed using our in-house Mutation
Identification Pipeline as previously described (31). All
called variants are scored and ranked using the Mutation
Identification Pipeline–weighted sum model, which uses
multiple parameters but emphasizes Mendelian inheri-
tance patterns and conserved, rare, and protein-damaging
variants.
Cell Culture
A skin biopsy (on each of the three patients and on
voluntary healthy control subjects) and a percutaneous
anterior tibial muscle biopsy (on the two patients born
2009 and 2014 and on voluntary healthy control subjects)
were performed, with fibroblasts and myoblasts harvested.
Primary skin fibroblasts (passages 7–14) were cultured
in minimal essential medium supplemented with Gluta-
Max I (Thermo Fisher Scientific, Waltham, MA), 10% FBS
(Sigma-Aldrich, St. Louis, MO), and penicillin/streptomy-
cin (BioWhittaker, Lonza, Morristown, NJ). Experiments
were performed with cells cultured to 70–80% confluence.
Culture medium was replaced every 2 to 3 days, and
cells were passaged using 0.05% trypsin (Thermo Fisher
Scientific).
Primary myoblasts (passages 5–15) were cultured in
F-10 mixture supplemented with GlutaMax I (Thermo
Fisher Scientific), 10% FBS (Sigma-Aldrich), 2.5 ng/mL
basic fibroblast growth factor (Thermo Fisher Scientific),
and penicillin/streptomycin. Experiments were performed
with cells cultured to 70–80% confluence. Culture medium
was replaced every 2 to 3 days (with basic fibroblast growth
factor added freshly each time), and cells were passaged
using 0.25% trypsin (Thermo Fisher Scientific).
Reconstitution of TXNIP Expression
Human TXNIP was cloned from blood cDNA into the ret-
roviral expression vector pBABE-gateway using Gateway
Technology (Thermo Fisher Scientific). In brief, primers
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(TXNIP_attB1_3 forward: 59-AAAAAGCAGGCTTCAUGG-
UGAUGUUCAAGAAGAUC-39 and TXNIP_attB2_3 reverse:
59-AGAAAGCTGGGTCUCUUCCACAUGCUCACUGC-39),
specific to TXNIP isoform 1 (NM_006472.5), carrying attB
adaptor tags (in boldface) were used to clone hTXNIP
into pDONR201, followed by recombination into pBABE-
gateway following the manufacturer’s instructions. The
final vector (pBABE-TXNIP) was confirmed by Sanger
sequencing.
Patient and control subject fibroblasts were trans-
formed with either empty pBABE-gateway or pBABE-
TXNIP using the retroviral phoenix system. For the pro-
duction of retrovirus, Phoenix-AMPHO cells (ATCC) were
transfected using Lipofectamine 3000 reagent (Thermo
Fisher Scientific) following the manufacturer’s instruc-
tions. After 7 h, fresh medium (DMEM-Glutamax [Thermo
Fisher Scientific] supplemented with 10% heat-inactivated
FBS [Thermo Fisher Scientific]) was added. Medium was
harvested and filtered 24, 36, and 48 h after transfection.
Retrovirus-containing medium was concentrated using
a Retro-X Concentrator (Clontech) following the manu-
facturer’s instructions. Patient or control subject fibro-
blasts were transduced after addition of 4 mg/mL
polybrene (Sigma-Aldrich) and cultured under puromycin
selection (0.15 mg/mL).
Mitochondrial Investigations in Isolated Muscle
Mitochondria and Specific Substrate Respiration in
Permeabilized Cells
Muscle mitochondria were isolated, and ATP production
rate as well as respiratory chain enzyme activities were
determined as described (32). To determine mitochondrial
respiration in myoblasts of specific complexes using selec-
tive mitochondrial substrates, an oxygraph chamber
(OROBOROS) was used at 37°C. Basal respiration was
measured in MIR05 medium, followed by permeabilization
with 4.07 mmol/L digitonin. State 3 respiration via com-
plex I was measured with the injection of 5 mmol/L
pyruvate and 2.5 mmol/L ADP (pyruvate), followed by
the injection of 0.5 mmol/L malate (malate). Complex II
activity (succinate) was determined by the addition of
0.5 mmol/L rotenone and 10 mmol/L succinate. Maximal
respiration (carbonyl cyanide m-chlorophenyl hydrazone
[CCCP]) was measured after addition of 2 mg/mL oligo-
mycin and titration with 0.5 mmol/L steps of CCCP.
Mitochondrial quality was controlled for by cytochrome
c addition. Finally, complex III was inhibited with 2.5 mmol/L
antimycin A.
Cellular Growth Rate
Growth rate was determined as previously described and
based on an increase in protein content as cells grow (33).
In brief, human primary myoblasts were seeded on multi-
well 6-well plates at a density of 1 3 104 cells/well. Cells
were fixed with 4% paraformaldehyde at 0, 1, 3, 5, and
7 days after seeding. Culture medium was changed every
2 days. After fixation, cells were rinsed once with PBS and
stained with staining solution (0.2% Coomassie Brilliant
Blue R-250, 10% acetic acid, and 40% methanol) for 1 h at
room temperature. The staining solution was discarded,
and the wells were rinsed eight times with distilled H2O.
Subsequently, 0.5 mL of elution solution (0.1 N NaOH in
50% methanol) was added and incubated for 1 h. Finally,
0.5 mL of 10% trichloroacetic acid was added to the well,
and 200 mL from each well was transferred to a multi–96-
well plate, and absorbance was determined at 595 nm.
Growth rate was determined in arbitrary units as an
increase in absorbance, setting the starting point at day 0.
TXN and TXN Reductase Levels
The cellular enzymatic activities of TXN and TXN reduc-
tase 1 (TXNRD1) were determined using an end-point
TXN-dependent insulin reduction assay as previously de-
scribed (34). The same lysates as those in which activities
were measured were also used for the determination of the
respective protein levels using Western blots.
RNA Extraction, Reverse Transcription, and
Quantitative PCR
Total RNA was extracted using Direct-zol RNA Kits (Zymo
Research, Irvine, CA) following the manufacturer’s instruc-
tions. The yield and purity of the RNA was determined
using a Nanodrop spectrophotometer (NanoDrop Tech-
nologies, Wilmington, DE). Total RNA (1 mg in 20 mL) was
reverse transcribed into cDNA (50 ng/mL final concentra-
tion) using the Maxima First Strand cDNA Synthesis Kit
for RT-qPCR (Thermo Fisher Scientific), with a mix of
random and oligo(dT) hexamer primers. The quantitative
PCR was performed from 10 ng of cDNA with the Lumi-
naris Color HiGreen qPCR Master Mix (Thermo Fisher
Scientific) with 600 nmol/L primers and using the PikoReal
Real-Time PCR System (Thermo Fisher Scientific) with
cycling conditions of: 50°C for 120 s; 95°C for 120 s;
40 cycles of 95°C for 15 s plus 55°C for 60 s; and 60°C
for 30 s. Primers (Sigma-Aldrich) were designed to span
intron–exon boundaries to avoid genomic DNA amplifica-
tion (all from Sigma-Aldrich). The expression ratio was
calculated using the DD threshold cycle method. b-Actin
expression was used to normalize the data and obtain
relative expression values with the comparative threshold
cycle method. Specificity of the PCR reaction was validated
by melting curve analysis. Samples from two patients and
two control subjects were separately pooled, and RNA was
extracted from five independent plates per pooled samples,
derived from separate cultures. The results are from these
five independent cultures each measured in duplicate.
Primer sequences are available upon request.
Immunofluorescence
Cultured myoblasts were fixed with 4% paraformaldehyde.
Cells were permeabilized, and nonspecific binding sites
were blocked with 0.1% Triton X-100 and 1% BSA diluted
in PBS. Subsequently, cells were stained using primary
antibody diluted in the aforementioned blocking solution
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followed by incubation with a secondary antibody conju-
gated with Alexa Fluor dye 594 for red detection (Thermo
Fisher Scientific). Nuclei were stained with Solution
8 DAPI PBS Staining Solution (ChemoMetec, Allerod,
Denmark), and coverslips were mounted using Fluoro-
mount G (Southern Biotechnology Associates, Birming-
ham, AL). Samples were examined using an LSM800
laser scanning confocal microscope (Zeiss, Oberkochen,
Germany).
Lactate Release as Measure of Glycolytic Rate
Lactate release to the extracellular milieu was used as an
indication of glycolytic flux and performed as previously
described (35,36). Cells were seeded on M6-multiwell
plates at a density of 1.5 3 105 cells/well. The day after,
the cells were changed to 1 mL/well of DMEM (Sigma-
Aldrich) containing 5 mmol/L glucose. A total of 50 mL of
medium was collected at different time points. At the end
of the experiment, cells were lysed (see protocol detailed
below for cell lysis), and protein content was determined
for normalization. The amount of lactate in the medium
was determined using the Lactate Reagent (Beckman
Coulter, Brea, CA), according to the guidelines provided
by the manufacturer. An additional subset of cells in
the same conditions, with the presence of 10 mmol/L
2-deoxyglucose, was used to determine the amount of
nonglycolytic-derived lactate and was subtracted from
the overall lactate production. The results depicted repre-
sent glycolysis-derived lactate production.
Extracellular Flux Analysis to Determine Mitochondrial
Respiration
Oxygen consumption rate (OCR) in real time was moni-
tored on intact fibroblasts and myoblasts using a Seahorse
Extracellular Flux Analyzer XF24-3 (Agilent) as previously
described with some modifications (36). Cells were seeded
at a density of 5 3 104 cells/well in a final volume of
100 mL. Before the experiment, the cells were changed to
bicarbonate- and FBS-free DMEM medium (Sigma-Aldrich)
containing either 5 mmol/L glucose plus 1 mmol/L sodium
pyruvate or 5 mmol/L sodium malate. After measuring
respiration in basal conditions, the fraction of respiration
coupled to ATP production was determined by subtracting
respiration after addition of the mitochondrial ATP syn-
thase inhibitor oligomycin (0.5 mmol/L) (EMD Millipore,
Billerica,MA) frombasal respiration. The difference between
respiration in the presence of the uncoupling ionophore
carbonyl cyanide 4-trifluoromethoxyphenylhydrazone
(FCCP) (0.5 mmol/L) (Sigma-Aldrich) and the mitochon-
drial complex III inhibitor antimycin A (4 mmol/L) (Sigma-
Aldrich) allowed us to determine the maximal respiratory
capacity in the presence of the aforementioned substrates
(glucose plus pyruvate or malate).
Pyruvate Dehydrogenase Activities
For determination of pyruvate dehydrogenase activities,
the patient-derived fibroblasts were sent to the National
Health Service Highly Specialised Services for rare mito-




Cell Lysis and Western Blot Analysis
Cells were washed once with PBS, placed on ice, and then
homogenized in a buffer containing: 20 mmol/L HEPES,
pH 7.4, 100 mmol/L sodium chloride, 100 mmol/L sodium
fluoride, 1% Triton X-100, 1 mmol/L sodium orthovana-
date (Na3VO4), 5 mmol/L EDTA, the Complete Protease
Inhibitor Cocktail (Roche Diagnostics, Mannheim, Ger-
many), and PhosStop phosphatase inhibitors (Roche Diag-
nostics). Samples containing the same amount of protein
were mixed with electrophoresis buffer containing SDS,
boiled for 5 min, and separated by gel electrophoresis on
4–12% precast acrylamide gels (Thermo Fisher Scientific).
The proteins were then transferred to nitrocellulose mem-
branes using an iBlot Dry Blotting system (Thermo Fisher
Scientific), and the membranes were blocked with 10%
nonfat dried milk in PBS plus 0.2% Tween-20 (PBST). The
blocked membranes were incubated overnight with
primary antibodies diluted in 5% nonfat dried milk-
containing PBST at 4°C. The antibodies used were: TXNIP
(1:2,000) (catalog number 40-3700; Invitrogen); b-actin
(1:2,000) (catalog number A5441; Sigma-Aldrich); TFAM
(1:2,000) (catalog number ab131607; Abcam); NDUFA9
(1:1,000) (catalog number 459100; MitoSciences, Life
Technologies); SDHA (1:5,000) (catalog number
ab14715; Abcam); UQCRC2 (1:10,000) (catalog number
PA5-30204; Thermo Fisher Scientific); COX5a (1:1,000)
(catalog number ab110262; Abcam); SDHA (1:5,000) (cat-
alog number ab14715; Abcam); ATP synthase-a subunit
(1:1,000) (catalog number 459240; Life Technologies);
LDHA (1:1,000) (catalog number 2012; Cell Signaling
Technologies); TIM23 (1:1,000) (catalog number
611222; BD Biosciences); TXN (1:500) (catalog number
sc58439; Santa Cruz Biotechnology, Dallas, TX); TXNRD1
(1:1,000) (catalog number sc18220; Santa Cruz Biotech-
nology); and GAPDH (1:1,000) (catalog number sc25778;
Santa Cruz Biotechnology).
The membranes were then rinsed three times in PBST
and incubated with the corresponding peroxidase-
conjugated secondary antibody (Santa Cruz Biotechnology)
for 1 h at room temperature. The immunoreactive proteins
were visualized by using an enhanced chemiluminescence
detection system (Amersham GE Healthcare, Buckinghamshire,
U.K.), and subsequent densitometric analysis was per-
formed with a ChemiDoc XRS scanner and Quantity
One 4.6.7 Software (Bio-Rad, Hercules, CA).
Imaging
Bright-field images were taken using a Zeiss Axiovert
40 CFL microscope (Zeiss) and photographed with a cou-
pled Zeiss Axiovert ICm1 camera using the Axio Vs40
v4.8.2.0 software (Zeiss).
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Statistics
Data are presented as mean 6 SEM. Statistical evaluation
was performed with the Student t test when comparing
two groups or two-way ANOVA when comparing several
groups using GraphPad Prism software (GraphPad Soft-
ware, San Diego, CA). Asterisks indicate significant differ-
ences between the indicated groups of data sets (*P, 0.05;
**P , 0.01; ***P , 0.005).
RESULTS
Identification and Characterization of Patients With
a TXNIP Gene Mutation Leading to Lack of TXNIP
Protein
Patient Characteristics
We investigated a family of Libyan descent with three
affected children who all presented with congenital lactic
acidosis. There is a fourth child in the family who has
compensated transposition of the heart, but no congenital
lactic acidosis. The parents are first cousins and normally
developed adults. The mother is healthy. The father is
rather tall and used to be obese but later reduced his
weight to normal and is physically very active.
The first child was a boy born in 2005 who had in-
creased plasma lactate up to maximally 9 mmol/L (normal
reference values 0.5–2.2 mmol/L) in the neonatal period.
He was treated successfully with dichloroacetic acid (DCA),
an acetic acid derivative clinically used to correct lactic
acidosis that is believed to increase pyruvate oxidation
through inhibition of pyruvate dehydrogenase kinase,
which will lower lactic acid production. The boy has since
required continuous DCA treatment. Neonatally, he had
episodes of hypoglycemia down to 1.8 mmol/L on days
2 and 3, and blood glucose has since been normal. He had no
stigmata or overt signs of cardiac, liver, or renal pathologies
in the neonatal period. Biochemical investigations of iso-
lated muscle mitochondria at 4 months showed suspected
deficiency of complex I of the respiratory chain, but a new
evaluation at 3 years gave normal results. At that time, he
also had a transient general hyperaminoaciduria. At 3 years,
slightly increased AST and alanine aminotransferase levels
and a profound hepatomegaly were noted with a homoge-
nous structure on ultrasound. A liver biopsy was performed,
revealing increased glycogen storage. Evaluation of plasma
amino acid levels showed normal values initially, but even-
tually deficiency of methionine developed, down to 9mmol/L
(normal reference values 11–42mmol/L). Serum creatinine
levels were often lower than normal, whereas other lab-
oratory investigations have been normal, including plasma
triglycerides, homocysteine, and cobalamine (Table 1). The
boy is slender and short with thin musculature, but he is
developing normally, and his liver size has normalized. He
is physically very active, swims a lot, and bikes quite far.
We have not measured blood glucose during exercise, but
there is no history of low glucose when asking. He has, thus
far, a normal development and is doing fine in school.
The second child is a girl born in 2009 who also pres-
ented with congenital lactic acidosis, requiring continuous
DCA treatment. She had no stigmata and normal organ
functions. Like her older brother, she also developed de-
ficiency of plasma methionine, down to 9 mmol/L. Serum
creatinine levels were also often low. Laboratory inves-
tigations were otherwise normal. Respiratory chain func-
tion was normal in isolated muscle mitochondria. Light
microscopy of the muscle biopsy showed almost complete
dominance of type 1 fibers. The girl is rather tall but
growing within the normal target height channel. She is
physically very active and, like her older brother, enjoys
swimming and bicycling. She has no problems with hypo-
glycemia when asked, and it has not been measured during
exercise. The only somatic problem noted is a mild allergy
to thyme, and the girl is developing normally.
The third child is a boy born in 2014, who also had
congenital lactic acidosis requiring DCA treatment. He
showed failure to thrive during his neonatal period with
muscular hypotonus and feeding difficulties. He has been
a slow developer and is currently under investigation for
problems within autism spectrum disorders. During his first
years, he had normal plasma methionine levels, but in the
most recent investigations, they were in the low normal
range, and during the revision of this paper, he developed
deficiency requiring increasedmethionine substitution ther-
apy, coinciding with the timing of methionine deficiency in
his siblings. He still shows slight muscular hypotonus and,
like his siblings, has low creatinine levels. He is also tall, but
growing within normal target height.
All three children are on continuous treatment with DCA
and methionine. For a summary of current glucose, ketone
bodies, and additional laboratory findings, see Table 1.
Genetic Investigations
Whole-exome sequencing was performed in the two eldest
siblings and the parents, revealing two homozygous single
nucleotide variants adjacent to each other in the two
siblings in the TXNIP gene (NM_006472). The variants
were c.174G.T, p.Gln58His and c.175G.T, p.Gly59*
(correctly denoted c.174_175delinsTT). The resulting pro-
tein change is thus an amino acid substitution at position
58 followed by a truncation. Sanger sequencing confirmed
that all three patients were homozygous, whereas both
parents were heterozygous for the two mutations. Other
inborn errors of metabolism affecting methionine metab-
olism were excluded. The patients had no additional high-
scoring mutations identified following an autosomal-
recessive inheritance in any other gene with known function
in intermediary metabolism. Neither of the two TXNIP
mutations were present in the Genome Aggregation Da-
tabase (gnomAD), which currently spans.123,000 exome
and 15,000 whole-genome sequences.
Validation of Lack of TXNIP Expression
We isolated primary fibroblasts and myoblasts from tib-
ial muscle biopsies, which were used for all further char-
acterizations in the current study. Using these cells, we
first confirmed byWestern blot analysis that the nonsense
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Table 1—Glucose homeostasis, ketone bodies, and additional laboratory findings for the three patients described in this study
Patient Glucose Ketone bodies Additional findings
Patient 1: boy,
13 years old
Normal fasting tolerance. Numerous blood
gases taken every month for several
years, and blood glucose has always
been normal.
A microdialysis investigation of tissue glu-
cose, glycerol, pyruvate, and lactate at
the age of 3 years, with determined
metabolite levels every 30th min for 24 h,
gave tissue glucose variation between
3.5 (during night) and 5.5 (daytime)
mmol/L.
A 24 h blood glucose profile at 10 years of
age was also performed with samples
before meals, 90 min after meals, and
twice during nighttime, which gave
fasting glucose 5.1 and peak glucose at
1700 h of 7.1 mmol/L.
Recently, fasting glucose of 4.3 and
4.7 mmol/L was measured with corre-
sponding fasting insulin of 4.8 and 4.3
mU/mL.
HbA1c 26–28 mmol/mol (reference: 28–39)
corresponding to 4.5–4.7% NGSP, 83–
89 mg/dL eAG, and 4.6–4.9 mmol/L
eAG.
At the age of 11 years, fasting
b-ketones in blood were
0.5 mmol/L
(reference: ,0.6 mmol/L). No
increased excretion of
ketones in urine.
Free fatty acids have not been ana-
lyzed. However, fasting glycerol
normal with 0.2 mmol/L (reference:
0.02–0.37) and triglycerides also
normal.
Total cholesterol mostly normal, once
elevated to 6.2 mmol/L (reference:
2.9–6.0).
HDL 0.8 mmol/L (reference: 0.84–1.9)
LDL 4.4 mmol/L (reference: 1.1–3.6)
LDL/HDL ratio 5.5 (reference: ,5.0)
Fasting acylcarnitine and fasting car-
nitine normal.
Cobalamin, folic acid, homocysteine,
and methylmalonic acid were all
normal.
Serum creatinine low inmany analyses,




Normal fasting glucose tolerance. Nu-
merous samples taken every month
for several years, and blood glucose
has always been normal.
A 24 h glucose profile at 5 years of age
with samples before meals, 90 min
after meals, and twice during night-
time showed a normal variation with
fasting glucose 4.8 and peak level
5.6 mmol/L after lunch.
More recently, fasting glucose 4.9 and
4.4 mmol/L with corresponding fast-
ing insulin 6.1 and 2.6 mU/mL taken
on different days.
HbA1c 28–30 mmol/mol (reference:
28–39) corresponding to 4.7–4.9%
NGSP, 89–92 mg/dL eAG, and
4.9–5.2 mmol/L eAG.
Two years ago, fasting b-ketones
0.6 (reference: ,0.6). No
increased urinary excretion.
Lactate at the same time was
5.4 mmol/L and glucose
4.4 mmol/L.
Fasting glycerol 0.13 mmol/L (refer-
ence: 0.02–0.37).
Triglycerides normal, 1.42 mmol/L
(reference: 0.42–2.7)
Total cholesterol 3.8 mmol/L (refer-
ence: 2.9–6.0)
HDL 0.99 mmol/L (reference: 0.84–1.9)
LDL 2.6 mmol/L (reference: 1.1–3.6)
LDL/HDL ratio 2.6 (reference: ,5.0)
Fasting acylcarnitine and fasting car-
nitine normal.
Cobalamin, folic acid, homocysteine,
and methylmalonic acid were all
normal.
Serum creatinine low inmany analyses,




Glucose levels in numerous samples
over the years have been normal.
A continuous glucosemonitoring test
was performed for 5 days, and glu-
cose variations remained within
normal reference values.
HbA1c 29 mmol/mol (reference: 28–39)
corresponding to 4.8% NGSP,
91 mg/dL eAG, and 5.1 mmol/L eAG.
No increased urinary excretion. Triglycerides normal, 1.26 mmol/L
(reference: 0.42–2.7)
Total cholesterol 3.6 mmol/L (refer-
ence: 2.9–6.0)
HDL 0.79 mmol/L (reference: 0.84–
1.9)
LDL 2.3 mmol/L (reference: 1.1–3.6)
LDL/HDL ratio 2.9 (reference: ,5.0)
Fasting acylcarnitine and fasting
carnitine normal.
Cobalamin, folic acid, homo-
cysteine, and methylmalonic acid
were all normal.
Serum creatinine low as in his sib-
lings, 16 mmol/L (reference: 31–
70)
The table summarizes current laboratory findings for the three patients as assessed during continuous treatment with DCA and
methionine. Normal reference values are given in parentheses. eAG, estimated average glucose; NGSP, National Glycohemoglobin
Standardization Program.
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mutation in the TXNIP gene indeed leads to absence of
detectable TXNIP protein (Fig. 1A and Supplementary
Fig. 1B).
Patient-Derived Cells Lacking TXNIP Have Normal
Growth Rates and Normal Morphology
We next set out to assess whether the absence of TXNIP
could lead to alterations in cell growth or cell morphology.
We determined cell growth rates in two sets of myoblasts
isolated from the patients over the course of 7 days in
complete culture medium, which were the same as for cells
isolated from healthy donors (Fig. 1B). Patient cells dis-
played no overt morphological alterations compared with
control subjects (Fig. 1C and Supplementary Fig. 1).
Patient-Derived Cells Lacking TXNIP Have Overtly
Normal TXN System Activities and Basally Activated
Nrf2 Activity
With TXNIP known as an endogenous TXN inhibitor, we
assessed TXN and TXNRD activities in lysates of patient
cells but could not detect any apparent effect compared
with control subjects (Supplementary Fig. 2). Using quan-
titative RT-PCR for analysis of Nrf2 target gene tran-
scripts, we found that most of the analyzed target genes
were strongly upregulated compared with control subjects,
thus suggesting a pronounced basal activation of Nrf2 in
the patient myoblasts (Fig. 2).
Patient Myoblasts Lacking TXNIP Have a Deficiency in
Respiration on Pyruvate but not on Malate
Considering the lactic acidosis in the TXNIP-deficient
patients and effects on glucose utilization in Txnip-
knockout mice (see INTRODUCTION), we next asked whether
the patient-derived cells would display any aberrations
in respiration on glucose. Strikingly, patient myoblasts
displayed significantly lower mitochondrial respiration
in the presence of glucose and pyruvate, both at the
basal level and upon uncoupling of mitochondrial res-
piration with the ionophore FCCP (Fig. 3A and B). The
same was also observed in patient fibroblasts (Supple-
mentary Fig. 3).
Given that TXNIP-null myoblasts do not display any
obvious morphological or proliferation-related alteration,
we hypothesized that they might have adapted their
metabolism to compensate for the impaired mitochon-
drial respiration on glucose and pyruvate. Assessing
glycolytic rates by measuring lactate release to the
extracellular milieu, this was found to be significantly
higher in myoblasts lacking TXNIP than in their control
counterparts (Fig. 3C). Moreover, when challenged with
the mitochondrial ATP-synthase inhibitor oligomycin, gly-
colytic rates were significantly upregulated in control
myoblasts, indicating a shift in metabolic profile toward
glycolysis to compensate for the absence of oxidative
phosphorylation-derived ATP. However, glycolytic rates
in TXNIP-null myoblasts did not change in the presence
of oligomycin, suggesting that they were already at a max-
imal rate of glycolysis (Fig. 3D).
To rule out that the significant impairment in glucose-
driven oxidative phosphorylation in the TXNIP-null myo-
blasts was due to a deficiency in the total amount of
mitochondria, we determined mitochondrial mass and
structure. Performing immunofluorescence and confocal
imaging with an antibody against the mitochondrial inner
membrane translocase subunit TIM23, we could not see
any apparent alteration in the amount or distribution of
the mitochondrial network in myoblasts from the patients
(Supplementary Fig. 4A). The levels of several integral
components of the mitochondrial machinery, including
the mitochondrial transcription factor A, TFAM, as well
as different components of respiratory complexes I, II, III,
and IV, and the subunit a of the ATP synthase, were also
similar to those in control cells (Supplementary Fig. 4B).
Moreover, using direct channeling of substrates to mito-
chondria in permeabilized cells, no differences could be
seen between the patient fibroblasts or myoblasts and
control subjects (Supplementary Fig. 5).
To determine whether the impairment in glucose- and
pyruvate-driven mitochondrial respiration was specific to
pyruvate channeling into mitochondria in a functional
cellular context, we next examined oxygen consumption
in intact myoblasts using malate as an alternative mito-
chondrial substrate. In this case, the TXNIP-deficient
patient myoblasts showed comparable respiratory rates
as control subjects, showing that malate can bypass the
block of mitochondrial respiration using pyruvate (Fig. 3E
and F). We also attempted to rescue respiration with
methyl pyruvate, which has higher membrane permeabil-
ity than pyruvate and enters directly into mitochondria,
but also methyl pyruvate could not restore respiration
in the patient cells, thereby indicating that there is a gen-
uine block of respiration on pyruvate (Fig. 4). We also sent
the patient-derived fibroblasts for analyses of pyruvate
dehydrogenase activities, which were all found to be
normal (patient 1: mean activity 0.6 nmol/mg protein/
min; patient 2: mean activity 0.62 nmol/mg protein/min;
and patient 3: mean activity 0.78 nmol/mg protein/min;
normal reference values: 0.6–0.9 nmol/mg protein/min).
In order to validate that the observed phenotype of the
patient-derived cells was indeed due to the lack of TXNIP
expression, we next reconstituted patient-derived fi-
broblasts with functional TXNIP using stable retroviral
transduction. This was done with fibroblasts rather than
myoblasts as they are easier to culture and transduce.
We first verified that TXNIP expression was established
using the pBABE-TXNIP vector compared with non-
transduced cells or negative control subjects using an
empty pBABE vector (Fig. 5A). We next performed
respiration analyses using these cells when cultured in
regular medium, which revealed that the respiration
in the patient-derived cells became indistinguishable
from healthy control subjects upon reconstitution with
TXNIP (Fig. 5B and C). The transduction did not affect
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the capacity of the cells to respire on malate (Supple-
mentary Fig. 6).
Collectively, these results strongly suggest that a lack
of TXNIP does not lead to mitochondrial impairment per
se, but rather to a specific deficiency in respiration on
pyruvate.
DISCUSSION
In this study, we have presented the features of a natural
human TXNIP deficiency with the cells from the affected
individuals displaying transcriptional profiles suggestive
of a strong basal activation of Nrf2 and diminished
mitochondrial respiration on glucose and pyruvate.
The results show that lack of TXNIP expression is non-
lethal in humans and possibly that the metabolic con-
sequences may be compatible with the notion that
TXNIP is a promising antidiabetic drug target. It is
important to note, however, that there is no indication
suggesting that the patients described in this study have
any other drivers promoting the development of di-
abetes (i.e., any theoretical inhibition of TXNIP in
a patient with diabetes cannot be directly compared
with the phenotype of the patients without diabetes
lacking TXNIP described in this study). Notwithstanding
this fact, we believe that some conclusions from our
study deserve to be pointed out.
We could not find any evident increase in TXN activity
in the patient-derived cells, which perhaps could have
been hypothesized based upon the original TXNIP stud-
ies identifying the protein as an endogenous TXN in-
hibitor. TXNIP binding to TXN involves the formation
of an intermolecular disulfide (37–39) that should be
stable under our conditions of preparing cell lysates, thus
suggesting that TXNIP was not severely impairing TXN
activity in control cells under the conditions tested in this
study or, conversely, that TXN activity is not necessarily
increased upon loss of TXNIP. It should, however, be
emphasized that several studies have suggested that the
modulation of glucose homeostasis as regulated by TXNIP
is not necessarily linked to its inhibition of TXN (40,41).
Also, in cells from a Txnip-knockout mouse model, it was
not possible to detect changes in Txn activities or protein
levels (22), although overexpression of a Txnip variant
binding Txn but not one incapable of binding Txn could
restore a Txnip-null phenotype (20). It is not clear
Figure 1—Primary myoblasts lacking TXNIP appear overtly normal. A: Western blot of TXNIP in primary myoblasts from two sets of primary
myoblasts isolated from healthy subjects (Control 1 and 2) and primary myoblasts from patients with a point nonsense mutation in the TXNIP
gene (Patients 1 and 2). b-Actin was used as loading control. Please note that this b-actin loading control is the same as depicted in
Supplementary Fig. 4, since antibodies against TXNIP, TFAM, SDHA, and COX5a were probed in the same membrane. B: Growth of control
(black) and TXNIP-null (red) primary myoblasts over 7 days. C: Bright-field images of primary myoblasts from patients and healthy donors.
a.u., arbitrary units.
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Figure 2—Strong basal activation of Nrf2 in TXNIP-null myoblasts. The graphs display the relative gene expression patterns for
a selected set of mainly Nrf2 target genes as determined by quantitative RT-PCR in primary myoblasts from control subjects (black) and
patients (red). Bars show mean 6 SEM (n = 5 independent cultures of cells using two pooled cellular RNA samples each for either
control subjects or patients; *P , 0.05). For information on full gene names and gene functions, please see www.genenames.org or
www.genecards.org.
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Figure 3—TXNIP-null myoblasts have deficient mitochondrial respiration on glucose and pyruvate but not on malate. A: Monitoring of OCR in
real time in the presence of 5 mmol/L glucose and 1 mmol/L pyruvate using extracellular flux analysis in primary myoblasts from healthy donors
(black) and patients (red). The sequential addition of oligomycin (O), FCCP (F), and antimycin (A) was used to determine ATP-coupled basal
respiration and maximal respiratory capacity, respectively. B: Assessment of ATP-coupled basal respiration and maximal respiratory capacity
in primary myoblasts from control subjects and patients, based on the results obtained in A. For A andB, data are represented asmean6 SEM
(n = 4 independent experiments, 5–8 wells per genotype per experiment). C: Glycolysis-derived lactate production in primary myoblasts from
control subjects (black) and patients (red). D: Lactate production at 6 h in primary myoblasts from control subjects and patients in the presence
(blue) or absence (black) of the ATP synthase inhibitor oligomycin (5 mmol/L). For C and D, bars represent mean 6 SEM (n = 3 independent
experiments, 2 wells per set of cells per experiment). E and F: Monitoring of OCR, ATP-coupled basal respiration, and maximal respiratory
capacity measured as inA andB but in the presence of 5mmol/Lmalate instead of glucose and pyruvate. Data are represented asmean6SEM
(n = 3 independent experiments, 5–6 wells per set of cells per experiment) (*P , 0.05; **P , 0.01).
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whether that latter effect was truly due to Txn binding or
to some other activity of Txnip that requires the same Cys
residue to be intact. It should be noted that regulation of
miRNA species or transcription factors are additional
functions of TXNIP (42). Concerning transcription factor
regulation, suppression of Nrf2 by TXNIP is perhaps
important. TXNIP expression is directly repressed by
Nrf2, and, conversely, TXNIP can possibly counteract
Nrf2 activation (8,11). This activity of TXNIP is yet
insufficiently characterized and requires further scrutiny,
but is supported by our findings with a strong induction
of many Nrf2 target genes in the TXNIP-deficient patient
cells. It is interesting, however, that we could not detect
altered TXN or TXNRD activities in the patient cells, since
diminished TXNRD1 activity typically activates Nrf2 (12)
but also that both TXN and TXNRD1 are Nrf2 target
genes that would be expected to be upregulated upon
Nrf2 activation. We indeed detected higher levels of TXN
and TXNRD1 transcripts in the patient cells, but not
higher protein or activity levels. Whether this particular
expression profile is a unique consequence of TXNIP
deletion is not known and should be studied further,
as should the possible mechanisms leading to Nrf2 acti-
vation upon loss of TXNIP.
We found the inefficiency of the patient cells to use
glucose and pyruvate for mitochondrial respiration, but
accepting malate as an alternative substrate, to be a notable
finding. This suggests that lack of TXNIP yields a rather
specific deficiency in glucose utilization and not in mito-
chondrial function per se, at least in the cell types studied
Figure 4—Lack of respiration in TXNIP-deficient myoblasts on pyruvate cannot be rescued by cell membrane–permeable methyl pyruvate.
Monitoring of OCR in real time in the presence of 2 mmol/L pyruvate (top) or 2 mmol/L methyl pyruvate (bottom) using extracellular flux
analysis in primary myoblasts from healthy donors (black) and patients (red). For details on the analyses, abbreviations, and statistics, see
legend of Fig. 3A, B, E, and F. As is well illustrated in this figure, the deficiencies in respiration of patient-derived myoblasts (red) compared
with control subjects (black) display very similar patterns irrespective of growth on pyruvate or on cell membrane permeable methyl pyruvate.
***P , 0.005.
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Figure 5—Reconstitution of TXNIP-null fibroblasts restores respiration on pyruvate. A: Immunoblot of TXNIP expression in control subject or
patient cells either nontransduced or transduced with empty control vector pBaBe or with pBaBe-TXNIP–expressing vector, with detection
of GAPDH used as loading control, as indicated in the figure. B: Monitoring of OCR in real time in the presence of 5 mmol/L glucose and
1 mmol/L pyruvate using extracellular flux analysis in primary myoblasts from healthy donors (black) and from patients (red), performed as in
Fig. 3. In total, each cell line was analyzed in three independent plates performed on separate days with 5–6 wells per plate, thereby resulting
in 15–18 recorded measurements per cell line. Data are represented as mean6 SEM (n = 3 independent experiments, 5–6 wells per cell type
per experiment).C: Basal ATP-coupled respiration (Resp.) andmaximal respiratory capacity derived from the experiment shown inB, defined
as in Fig. 3 (*P , 0.05).
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in this paper. The finding is partly consistent with studies
in mice, showing that Txnip ablation leads to a deficiency
in pyruvate dehydrogenase activity and a subsequent
decrease in pyruvate-driven mitochondrial respiration,
at least in cardiomyocytes (21). However, we could not
find evidence of distorted pyruvate dehydrogenase activity
in the patient-derived fibroblasts, and the mechanisms
involved for the lack of pyruvate-driven respiration in
these cells are thereby not fully explained. The metabolic
shift perhaps relates to the findings in cancer cells, in
which a constitutively upregulated Nrf2 yields a prefer-
ence in glucose metabolism for anabolic pathways com-
bined with glutamine catabolism, leading to increased
production of lactate from malate through formation of
pyruvate (43). This could yield a functional mitochon-
drial deficiency of malate, which was a reason for us to
analyze mitochondrial respiration upon additional
malate supplementation. It is thus possible that the
increased lactic acidosis seen in the TXNIP-deficient
patients is due to a combination of diminished usage
of pyruvate by mitochondria, as well as increased pro-
duction of pyruvate frommalate derived from glutamine
catabolism. In both cases, the increased levels of pyru-
vate would be expected to yield an increased production
of lactate. It should be noted, however, that in this
study, we have only been able to characterize primary
myoblasts and fibroblasts from these patients, and it is
possible that the metabolic pathways affected by a lack
of TXNIP are different in other tissues, such as liver or
pancreas. Indeed, both TXNIP and Nrf2 are known to
display tissue-specific effects in their strong influences
on metabolic pathways and tissue integrity (3,15,25,30).
Total Txnip knockout in mice has, however, also been
reported to yield increased serum lactate levels com-
pared with control subjects, at least under fasting con-
ditions (44).
The patients who we described in this study have
undetectable levels of TXNIP protein, with lactic acidosis
and low serum methionine as their common major pre-
senting signs. Evidence of hypoglycemia, liver involve-
ment, and muscle weakness were also noted but not in
all three siblings. The lactic acidosis, with all three siblings
responding well to the classical treatment with dichloro-
acetate, although this can have variable success in children
(45), is likely to be explained by the inefficient respiration
on pyruvate that we found using the patient-derived cells,
but as of today, we have no explanation for the clinical
presentation with low serum methionine. It should be
noted that methionine can be an important source of
reducing power through synthesis of glutathione, which
is used in mice upon conditional deletion of Txnrd1
in hepatocytes with or without concomitant deletion
of Txn (46,47). Such increased usage of methionine should
however not be needed in cells or tissues lacking TXNIP;
on the contrary, the TXN system would be presumed to
have increased activities if anything, thus minimizing the
need for methionine as a source of reducing equivalents.
However, because we also found Nrf2 to be activated in the
patient-derived cells, it could be possible that an increased
glutathione synthesis, as activated by Nrf2, would increase
methionine usage. Other reasons for low serum methio-
nine in the patients not related to cysteine or glutathione
synthesis may involve some yet unidentified lack of a
TXNIP-dependent process helping to maintain physio-
logical serum methionine levels. In Txnip-null mice, the
detrimental effects of methionine- and choline-deficient
diet are aggravated compared with control subjects (48)
but we are not aware of any study that has investigated
functional links between TXNIP status and methionine
levels in serum. This relationship is clearly another aspect
of TXNIP deficiency that deserves to be further studied. It
is perhaps likely that an altered metabolic flux of methi-
onine in liver of the TXNIP-deficient patients is involved
that, however, is difficult to experimentally probe in
a clinical setting.
We conclude that the clinical and cellular phenotypes
of patients lacking TXNIP suggest that this protein has
rather specific regulatory effects in humans. Its defi-
ciency is evidently nonlethal, and the major clinical pre-
sentations are lactic acidosis and low serum methionine,
with little or no other overt pathophysiology. Glucose
utilization for mitochondrial respiration in the patient-
derived cells was impaired mainly due to a deficiency of
the mitochondria to use pyruvate. These findings may thus
collectively indicate that inhibition of TXNIP can indeed be
beneficial in humans for the treatment of diabetes, as has
been proposed, although it should be noted that a genetic
lack of TXNIP in patients without diabetes does not
necessarily mimic effects of drug-mediated TXNIP inhibi-
tion in therapy of diabetes. Possible main side effects of
TXNIP inhibition in humans would, based upon our find-
ings, be lactic acidosis and lowered serum methionine
levels.
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